Invasive pulmonary aspergillosis (IPA) is an important cause of morbidity and mortality in immunocompromised patients. We hypothesized that simultaneous inhibition of biosynthesis of ergosterol in the fungal cell membrane and (1→3)-β-d-glucan in the cell wall, respectively, by the antifungal triazole isavuconazole (ISA) and the echinocandin micafungin (MFG) may result in improved outcomes in experimental IPA in persistently neutropenic rabbits. Treatments included ISA at 20 mg/kg of body weight/day (ISA20), 40 mg/kg/day (ISA40), and 60 mg/kg/day (ISA60); MFG at 2 mg/kg/day (MFG2); combinations of ISA20 and MFG2, ISA40 and MFG2, and ISA60 and MFG2; and no treatment (untreated controls [UC]). The galactomannan index (GMI) and (1→3)-β-d-glucan levels in serum were measured. The residual fungal burden (number of CFU per gram) was significantly reduced in ISA20-, ISA40-, ISA60-, ISA20-MFG2-, ISA40-MFG2-, and ISA60-MFG2-treated rabbits compared with that in MFG2-treated or UC rabbits ( < 0.01). Measures of organism-mediated pulmonary injury, lung weights, and pulmonary infarct score were lower in ISA40-MFG2-treated rabbits than in rabbits treated with ISA40 or MFG2 alone ( < 0.01). Survival was prolonged in ISA40-MFG2-treated rabbits in comparison to those treated with ISA40 or MFG2 alone ( < 0.01). These outcome variables correlated directly with significant declines in GMI and serum (1→3)-β-d-glucan levels during therapy. The GMI correlated with measures of organism-mediated pulmonary injury, lung weights ( = 0.764; < 0.001), and pulmonary infarct score ( = 0.911; < 0.001). In summary, rabbits receiving combination therapy with isavuconazole and micafungin demonstrated a significant dose-dependent reduction in the residual fungal burden, decreased pulmonary injury, prolonged survival, a lower GMI, and lower serum (1→3)-β-d-glucan levels in comparison to rabbits receiving isavuconazole or micafungin as a single agent.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571280PMC
http://dx.doi.org/10.1128/AAC.00305-17DOI Listing

Publication Analysis

Top Keywords

isavuconazole micafungin
12
isa40 mfg2
12
1→3-β-d-glucan levels
12
pulmonary injury
12
combination therapy
8
therapy isavuconazole
8
invasive pulmonary
8
pulmonary aspergillosis
8
rabbits
8
residual fungal
8

Similar Publications

Multiparametric LC-MS/MS method for simultaneous determination of eleven antifungal drugs and metabolites in human plasma.

J Pharm Biomed Anal

January 2025

Department of Pharmacology, Montpellier University Hospital, Avenue du Doyen Gaston Giraud, Montpellier 34090, France; Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), INSERM, University Montpellier, Montpellier 34090, France. Electronic address:

Article Synopsis
  • A new liquid chromatography-tandem mass spectrometry method has been created to measure 11 antifungal drugs and their metabolites in human plasma, essential for monitoring treatment in immunocompromised patients with fungal infections.
  • * This method not only optimizes settings and preparation techniques for accurate detection but also follows strict FDA and EMA guidelines to ensure reliability and performance.
  • * With a quick processing time of 5 minutes per sample and minimal plasma requirement, this method supports better antifungal therapy management in critical care settings.
View Article and Find Full Text PDF
Article Synopsis
  • Invasive fungal infections are common in hospitals and lead to significant health risks, affecting many patients with high rates of morbidity and mortality.
  • The study aimed to identify the top 10 most influential articles from 2018 to 2023 regarding the treatment of these infections using a three-step consensus approach with expert panels.
  • The final list of recommended publications focuses on treating conditions like invasive aspergillosis, candidiasis, and cryptococcosis, serving as a valuable resource for clinicians to enhance their antifungal treatment strategies.
View Article and Find Full Text PDF

Emerging infections in Taiwan: clinical and environmental surveillance.

JAC Antimicrob Resist

August 2024

Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Objectives: This study aimed to investigate the prevalence and characteristics of clinical and environmental isolates in Taiwan.

Methods: isolates obtained from patients at three hospitals and from 530 soil samples across Taiwan were screened. , confirmed by calmodulin sequencing, was subjected to antifungal susceptibility testing and analyses.

View Article and Find Full Text PDF

Introduction: Midostaurin is a multikinase inhibitor approved for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukemia (AML). Azole antifungal medications are commonly used in AML and are known to interact with anti-cancer drugs such as midostaurin through the CYP3A pathway. However, there are no midostaurin related dose modifications recommended with strong CYP3A inhibitors.

View Article and Find Full Text PDF
Article Synopsis
  • Jazan Industrial Economic City (JIEC) is a hub for various heavy industries in Saudi Arabia, including petroleum and water desalination, which produce significant amounts of industrial wastewater containing toxic substances.
  • The study focuses on isolating 32 fungal strains from this wastewater that can tolerate multiple heavy metals and have efficient bioremediation capabilities for pollutants like crude oil and polycyclic aromatic hydrocarbons.
  • Among these fungi, isolate JAZ-20 exhibited outstanding bioremoval efficiency, achieving up to 100% removal of several harmful pollutants and demonstrating low levels of antibiotic resistance within the mycobiome.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!